Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 12Prostatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 4Prostatic Neoplasms, Castration-Resistant 4Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Lymphoid Interstitial Pneumonia 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma 2Anatomic Stage I Breast Cancer AJCC v8 2Vaccinia 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Non-small Cell Lung Cancer Metastatic 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Sunitinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Docetaxel × 30 days × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT04928846 2026-06-02

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AbbVie

Phase 3 Recruiting
698 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡